# Pomalidomide-PEG1-azide

**Cat. No.:** HY-133138

**CAS No.:** 2133360-04-8

**Molecular Formula:** $C_{17}H_{16}N_6O_6$

**Molecular Weight:** 400.35

**Target:** E3 Ligase Ligand-Linker Conjugates

**Pathway:** PROTAC

**Storage:** 4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



## SOLVENT & SOLUBILITY

**In Vitro**

DMSO : 62.5 mg/mL (156.11 mM; ultrasonic and warming and heat to 60°C)

| Preparing Stock Solutions | Solvent / Mass / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|---|
| | 1 mM | 2.4978 mL | 12.4891 mL | 24.9781 mL |
| | 5 mM | 0.4996 mL | 2.4978 mL | 4.9956 mL |
| | 10 mM | 0.2498 mL | 1.2489 mL | 2.4978 mL |

Please refer to the solubility information to select the appropriate solvent.

## BIOLOGICAL ACTIVITY

**Description**

Pomalidomide-PEG1-azide is a E3 ligase lgand-linker conjugate. Pomalidomide-PEG1-azide incorporates the Pomalidomide based cereblon ligand and a linker.?Pomalidomide-PEG1-azide?can be used to design a?PROTAC BRD4 Degrader-1 (HY-133131)[1]. Pomalidomide-PEG1-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

## REFERENCES

[1]. Zhang F, et al. Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide. Bioorg Med Chem. 2020 Jan 1;28(1):115228.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA